NIH Funding & Biotech Deals: Readout LOUD Podcast
NIH Grant Cuts, FDA Clarity, and a $10 Billion Biotech Deal: This Week in Biotech
Table of Contents
This week in biotech, we’re diving into a legal battle over NIH funding, questioning the FDA’s definition of “transparency,” and tracking another major acquisition signaling a heating-up M&A landscape.
NIH Funding Under Fire: A Legal Playbook Emerges
The National Institutes of Health (NIH) is facing increasing scrutiny over recent grant terminations, and a newly obtained memo from the Department of Health and human Services (HHS) is shedding light on the legal justification being used. STAT’s Anil Oza has been leading the charge on this story, and he joins us on this week’s readout LOUD podcast to unpack the details.
The memo outlines the framework HHS is employing to defend thes cuts in court, as legal challenges mount. The terminations have sparked controversy, raising questions about the process and potential political motivations behind the decisions. oza’s reporting reveals a purposeful legal strategy, offering a deeper understanding of the battles being waged over federal research funding.
You can read more about Anil’s coverage here and here.
FDA transparency: A skeptical Look at Commissioner Makary’s Push
FDA Commissioner Marty Makary recently announced the publication of hundreds of letters the agency sent to drugmakers when their medicines were initially rejected. Framed as a move towards “radical transparency” in drug reviews, the initiative has been met with some skepticism.
The key issue? The letters released pertain only to drugs that were ultimately approved. This means the facts contained within them is arguably less valuable, as it doesn’t reflect the full spectrum of reasons for rejection. Furthermore, Commissioner Makary has yet to commit to releasing “complete response letters” – the official rejections - for drugs that didn’t make it through the approval process under his leadership.
While increased transparency is generally a positive step,this selective release raises questions about the true intent and scope of the FDA’s efforts. Is it truly about openness, or simply a curated presentation of successes?
You can find STAT’s ongoing coverage of the FDA here.
Biotech M&A Heats Up: Merck‘s $10 Billion Bet on Verona Pharma
The biotech mergers and acquisitions (M&A) market is showing signs of life, and this week saw a significant deal: Merck announced its intention to acquire Verona Pharma for a hefty $10 billion.
This acquisition underscores a broader trend – large pharmaceutical companies are actively seeking to bolster their pipelines and secure new revenue streams through strategic acquisitions of promising biotech firms. Verona Pharma’s focus on lung disease, notably its lead candidate for chronic obstructive pulmonary disease (COPD), likely made it an attractive target for Merck, especially as the company faces patent cliffs on blockbuster drugs like Keytruda.
This deal is another indicator that the biotech landscape is shifting, with consolidation becoming a key strategy for navigating the challenges of drug development and market competition. You can read more about the Merck-Verona deal here.Listen to the full discussion on The Readout LOUD podcast:
And don’t forget to subscribe: